Hantz Financial Services Inc. Decreases Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Hantz Financial Services Inc. decreased its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 33.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,063 shares of the medical equipment provider’s stock after selling 25,334 shares during the quarter. Hantz Financial Services Inc.’s holdings in Smith & Nephew SNATS were worth $1,643,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. increased its position in shares of Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the last quarter. Bank of America Corp DE increased its position in shares of Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after purchasing an additional 575,666 shares during the last quarter. Todd Asset Management LLC increased its position in shares of Smith & Nephew SNATS by 30.2% during the 4th quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock valued at $30,992,000 after purchasing an additional 219,348 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Smith & Nephew SNATS by 45.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider’s stock valued at $34,038,000 after purchasing an additional 293,418 shares during the last quarter. Finally, ABC Arbitrage SA increased its position in shares of Smith & Nephew SNATS by 10.9% during the 4th quarter. ABC Arbitrage SA now owns 757,956 shares of the medical equipment provider’s stock valued at $24,869,000 after purchasing an additional 74,504 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Down 0.9%

NYSE SNN opened at $30.16 on Thursday. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a one year low of $28.40 and a one year high of $38.79. The stock has a 50 day moving average price of $31.75 and a 200-day moving average price of $33.05.

Smith & Nephew SNATS (NYSE:SNN) last posted its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, equities analysts forecast that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current year.

Smith & Nephew SNATS Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, May 27th. Investors of record on Friday, March 27th were given a $0.482 dividend. The ex-dividend date was Friday, March 27th. This represents a yield of 304.0%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SNN. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday. Canaccord Genuity Group cut their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research note on Monday, May 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.93.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.